Abstract
INTRODUCTION AND OBJECTIVES: Background: Although little advance in the treatment of metastatic urothelial carcinoma of the bladder has been achieved in the recent years, several phase–trials of gemcitabine and paclitaxel as 2nd-line chemotherapy in patients with metastatic urotherial carcinoma were performed. PURPOSE: Gemcitabine/Paclitaxel (GP) and Best supportive care (BSC) were compared in patients with metastatic urothelial carcinoma who have previously been treated with platinum based chemotherapy. PATIENT: Fifty-two patients with metastatic urotherial carcinoma who were resistant to methotrexate,vinblastin,doxorubicin and cisplatin(M-VAC) or gemcitabine and cisplatin (GC) chemotherapy regimen were evaluated. GP ARM; 29 nine patients were treated with chemotherapy consisting of intravenous gemcitabine 2,500mg/m2 and paclitaxel 150mg/m2 every 2 weeks. BSC ARM; 23 patients were treated with only BSC. METHODS: Toxicities were evaluated in GP ARM patients. We clarified whether overall survival (OS) is related to 2nd line GP treatment using the Kaplan-Meier method, log-rank test. Multivariate analyses of baseline parameters with respect to OS were performed. RESULTS: Toxicities were mild, and no life-threatening complications occurred. The objective of median 130 days survival advantage favoring GP was achieved (Figure, 70 vs. 200days), with statistical significance (p 0.015). Multivariate analyses of baseline parameters with respect to OS showed statistically significant effect of GP (Table, HR: 0.4119 95%CI 0.1849-0.9174). CONCLUSIONS: GP therapy is a tolerable and active regimen in metastatic urothelial carcinoma who have previously been treated with platinum based chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.